Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
Latest Information Update: 17 Nov 2024
At a glance
- Drugs Ritlecitinib (Primary)
- Indications Alopecia areata
- Focus Expanded access; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 02 Sep 2022 New trial record